Alaunos Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -135.6% | -106.0% | -83.0% |
| FY2022 | -97.9% | -97.9% | -58.1% |
| FY2023 | -74.2% | -74.2% | -56.6% |
| FY2024 | -226.8% | -226.8% | -169.8% |
| FY2025 | -194.0% | -194.0% | -140.8% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -135.6% | -106.0% | -83.0% |
| FY2022 | -97.9% | -97.9% | -58.1% |
| FY2023 | -74.2% | -74.2% | -56.6% |
| FY2024 | -226.8% | -226.8% | -169.8% |
| FY2025 | -194.0% | -194.0% | -140.8% |